{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:55:56Z","timestamp":1781056556678,"version":"3.54.1"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Despite antiretroviral therapy (ART) scale\u2010up among people living with HIV (PLHIV), those with advanced HIV disease (AHD) (defined in adults as CD4 count &lt;200 cells\/mm<jats:sup>3<\/jats:sup> or clinical stage 3 or 4), remain at high risk of death from opportunistic infections. The shift from routine baseline CD4 testing towards viral load testing in conjunction with \u201cTest and Treat\u201d has limited AHD identification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used official estimates and existing epidemiological data to project deaths from tuberculosis (TB) and cryptococcal meningitis (CM) among PLHIV\u2010initiating ART with CD4 &lt;200 cells\/mm<jats:sup>3<\/jats:sup>, in the absence of select World Health Organization recommended diagnostic or therapeutic protocols for patients with AHD. We modelled the reduction in deaths, based on the performance of screening\/diagnostic testing and the coverage and efficacy of treatment\/preventive therapies for TB and CM. We compared projected TB and CM deaths in the first year of ART from 2019 to 2024, with and without CD4 testing. The analysis was performed for nine countries: South Africa, Kenya, Lesotho, Mozambique, Nigeria, Uganda, Zambia, Zimbabwe and the Democratic Republic of Congo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The effect of CD4 testing comes through increased identification of AHD and consequent eligibility for protocols for AHD prevention, diagnosis and management; algorithms for CD4 testing avert between 31% and 38% of deaths from TB and CM in the first year of ART. The number of CD4 tests required per death averted varies widely by country from approximately 101 for South Africa to 917 for Kenya.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This analysis supports retaining baseline CD4 testing to avert deaths from TB and CM, the two most deadly opportunistic infections among patients with AHD. However, national programmes will need to weigh the cost of increasing CD4 access against other HIV\u2010related priorities and allocate resources accordingly.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jia2.26070","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T10:28:11Z","timestamp":1678184891000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modelling the impact of CD4 testing on mortality from TB and cryptococcal meningitis among patients with advanced HIV disease in nine countries"],"prefix":"10.1002","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-0900","authenticated-orcid":false,"given":"Ikwo Kitefre","family":"Oboho","sequence":"first","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Paulin","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Avenir Health  Glastonbury Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Jordan","sequence":"additional","affiliation":[{"name":"Division of Foodborne Waterborne and Environmental Diseases Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Kirking","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfriede","family":"Agyemang","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Jean","family":"Podewils","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"},{"name":"Denver Health and Hospital Authority  Denver Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel","family":"Pretorius","sequence":"additional","affiliation":[{"name":"Avenir Health  Glastonbury Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of Foodborne Waterborne and Environmental Diseases Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Chiller","sequence":"additional","affiliation":[{"name":"Division of Foodborne Waterborne and Environmental Diseases Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"},{"name":"U.S. Office of Global AIDS Coordinator and Health Diplomacy  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Bhatkoti","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray W.","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Sarita","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB Centers for Disease Control and Prevention  Atlanta Georgia USA"},{"name":"Emory Rollins School of Public Health  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"UNAIDS.Global HIV & AIDS statistics \u2014 2021 fact sheet.2021."},{"key":"e_1_2_12_3_1","unstructured":"WHO.Managing advanced HIV disease and rapid initiation of antiretrovial therapy.2017."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001606"},{"key":"e_1_2_12_5_1","unstructured":"WHO.Global tuberculosis report.2018."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30243-8"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328322ffac"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00137-X"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6621a3"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy045"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25546"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","unstructured":"WHO.Lateral flow urine lipoarabinomannan assay (LF\u2010LAM) for the diagnosis of active TB in people living with HIV; policy update.2019.","DOI":"10.1002\/14651858.CD011420.pub3"},{"key":"e_1_2_12_13_1","unstructured":"WHO.Guidelines for the diagnosis prevention and management of cryptococcal disease in HIV\u2010infected adults adolescents and children.2018."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002357"},{"issue":"4","key":"e_1_2_12_15_1","article-title":"Using the TIME model in Spectrum to estimate tuberculosis\u2010HIV incidence and mortality","volume":"28","author":"Pretorius C","year":"2014","journal-title":"AIDS"},{"key":"e_1_2_12_16_1","unstructured":"Avenir Health.Spectrum Manual: Spectrum System of Policy Models.2022. Available from:http:\/\/avenirhealth.org\/Download\/Spectrum\/Manuals\/SpectrumManualE.pdf"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170976"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615822"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001316"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix872"},{"key":"e_1_2_12_21_1","unstructured":"The Stop TB Partnership.High burden countries for tuberculosis.2019. Geneva World Health Organization.https:\/\/www.stoptb.org\/securing-quality-tb-care-all\/high-burden-countries-tuberculosis"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000484"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001120"},{"issue":"5","key":"e_1_2_12_24_1","article-title":"Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV\u2010positive adults","volume":"2016","author":"Shah","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_25_1","volume-title":"WHO guidelines approved by the Guidelines Review Committee. Systematic screening for active tuberculosis: principles and recommendations.","author":"World Health Organization","year":"2013"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00201711"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.1.18932"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01092-2"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.13112.1"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30001-5"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00499-6"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2020.01.009"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00441-20"},{"key":"e_1_2_12_34_1","unstructured":"PEPFAR.PEPFAR 2022 country operational plan guidance for all PEPFAR countries.2022."},{"key":"e_1_2_12_35_1","unstructured":"World Health Organization.WHO prequalification of in vitro diagnostics: public report. Product: VISITECT CD4 Advanced Disease.2020."}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.26070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.26070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.26070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T05:12:08Z","timestamp":1723007528000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.26070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/jia2.26070"],"URL":"https:\/\/doi.org\/10.1002\/jia2.26070","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"2022-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e26070"}}